News

It shouldn’t be just about QALYs and cost. An ISPOR panel today discussed how best to incorporate the patient perspective into value assessment.

Dr. Vivian Lee of Verily Life Sciences addresses if value-based care programs have steered U.S healthcare away from the problems of fee-for-service at a virtual ISPOR meeting today. Lee also shares her thoughts on if the pandemic changed her views of American healthcare.

"COVID. KNOW MORE," is an innovative, timely new initiative empowering Black Americans with the latest information, resources, and updates on COVID-19.

The model has put the patient at the center of healthcare.

Federally Qualified Health Centers have been the safety net for individuals in need for decades. However, even with increasing demand for their services – tripling the number of patients served to more than 28 million since 2000 – FQHCs are not immune from challenges stemming from the pandemic.

Too many study volunteers randomized to the 325-mg dose switched to the 81-mg one to settle the dosage issue But ADAPTABLE is still being celebrated as the kind of "pragmatic study'' that can be a less expensive, more realistic version of the RCT.

The pandemic revealed the fragility, vulnerabilities and unique dangers of working in the healthcare setting. Chief among these was the eroded ability to service patients when there were staff availability issues.

A 13% decline in the past year continues downward. Some of the decline might be explained by pandemic-related drop in healthcare utilization.

Breaches in online vaccination schedulers are the among the security problems the healthcare sector is scrambling to fix.

Providers are moving toward acceptance; the rules are here to stay. Payers recognize that people need to know prices.

Smaller providers that have seen sharp declines in revenue may be acquisition targets for large healthcare systems.

Longer half-lives mean less frequent administration and improved quality of life.

The drugs in development include Biogen’s controversial treatment for Alzheimer’s disease and three new drugs for atopic dermatitis.

The supply side of the COVID-19 vaccine rollout has garnered most of the attention. But a recent survey on American beliefs about the vaccines suggests that the bigger problem may be on the demand side of the equation.

Teva is making the first generic version of Absorica (isotretinoin), a drug for the treatment of severe acne.

Young adults did not have significantly better sleep when using blue light filters on their smartphones in the hour before bed, according to a new study.

There’s no going back to the ways of working before COVID-19’s arrival, say many in the industry. Insurers and PBMs are reducing their footprint as work becomes part remote, part in person.

Copay accumulators are a common feature in health insurance plans sold on the ACA exchanges, according to a recent report from an AIDS advocacy group that wants the Biden administration to reverse a decision made by the Trump administration that allowed continued use of accumulators.

Emphasizing data efficiencies and quality will benefit payers and providers — and patients.

Researchers find that it is quite the opposite.

Sleep problems are associated with increased risk of chronic diseases.

The study, which will be presented next week during the 70th American College of Cardiology Scientific Session, is the first to examine how chest pain is managed among adults who are too young for Medicare.

Deaths by suicide and by substance use disorders have reached epidemic proportions, creating the tragic “perfect storm” of epidemics within a pandemic. A survey conducted by PRECISIONvalue of population health priorities among health systems and health plans since the onset of Covid-19 suggests that while mental health conditions have risen in priority, opioid use disorders have become alarmingly deprioritized.

A report by the Agency for Healthcare Research and Quality suggested existing evidence on continuous positive airway pressure devices is not robust enough to be clinically meaningful.

The Institute for Clinical and Economic Review's price range is far below the $50,000 per year envisioned by some market analysts.

Briana Contreras, associate editor of Managed Healthcare, speaks with Linda Matthews, president of BioCare, a leading specialty distributor of life-saving therapies, in this week's episode of Tuning In to the C-Suite podcast. The two discussed the evolution of these therapies over the last decade and most importantly how to expand and diversify a healthcare business.